(Q40446595)

20 September 2017

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma (English)

1 reference

20 September 2017

1 reference

9

Jeffrey A Meyerhardt

1 reference

20 September 2017

11

Charles S Fuchs

1 reference

20 September 2017

Andrew X Zhu

1

1 reference

20 September 2017

Keith Stuart

2

1 reference

20 September 2017

Lawrence S Blaszkowsky

3

1 reference

20 September 2017

Alona Muzikansky

4

1 reference

20 September 2017

Donald P Reitberg

5

1 reference

20 September 2017

Jeffrey W Clark

6

1 reference

20 September 2017

Peter C Enzinger

7

1 reference

20 September 2017

Pankaj Bhargava

8

1 reference

20 September 2017

Kerry Horgan

10

1 reference

20 September 2017

David P Ryan

12

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

20 September 2017

1 reference

20 September 2017

110

1 reference

20 September 2017

3

1 reference

20 September 2017

581-589

1 reference

Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines

20 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

Estimating the world cancer burden: Globocan 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Hepatocellular carcinoma: the need for progress.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Tyrosine kinases as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22829

7 January 2021

Identifiers

DOI

10.1002/CNCR.22829

1 reference

20 September 2017

1 reference